GlassScriptPhysician profile
Beth Dombrowski
NPI 1124448428
$3,357.73
in general payments reported to CMS, 2019-2025
28 companies · $937 in 2025
The $937 reported for 2025 was more than what 86% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $116 · 2022: $527 · 2023: $718 · 2024: $1,060 · 2025: $937.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,715.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,714.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $675.59 | 2021-2025 | |
| Novo Nordisk INC | $579.44 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $305.24 | 2024-2025 | Farxiga, Airsupra, Breztri |
| Amgen INC. | $286.38 | 2023-2025 | Evenity, Enbrel, Prolia |
| E.R. Squibb & Sons, L.L.C. | $242.82 | 2022-2024 | Eliquis |
| Pfizer INC. | $213.76 | 2023-2025 | |
| Lilly USA, LLC | $163.60 | 2022-2025 | Mounjaro, Zepbound, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $110.67 | 2022-2025 | Ofev, Jascayd |
| Glaxosmithkline, LLC. | $98.31 | 2022-2023 | Benlysta, Nucala, Shingrix |
| Novartis Pharmaceuticals Corporation | $94.12 | 2022-2025 | |
| Radius Health, INC. | $73.21 | 2023-2024 | Tymlos |
| Exact Sciences Corporation | $70.56 | 2023-2024 | Cologuard Collection Kit |
| Abbott Laboratories | $66.41 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Ucb, INC. | $47.11 | 2025 | Bimzelx |
| Exeltis, USA INC. | $44.88 | 2023 | Slynd |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $36.89 | 2025 | Austedo Xr |
| Sandoz INC. | $34.70 | 2024 | Hyrimoz |
| Dexcom, INC. | $32.34 | 2025 | Dexcom G6 Transmitter |
| Organon LLC | $22.57 | 2022 | |
| Sanofi-Aventis U.S. LLC | $22.26 | 2023 | |
| Medtronic, INC. | $21.24 | 2022 | |
| Sobi, INC | $21.06 | 2022 | |
| Coopersurgical, INC. | $20.02 | 2025 | Paragard T 380a |
| Janssen Biotech, INC. | $19.60 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $16.95 | 2025 | Abilify Asimtufii |
| Eisai INC. | $16.88 | 2021 | |
| Xeris Pharmaceuticals, INC. | $15.65 | 2022 | |
| Genentech USA, INC. | $5.47 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Dombrowski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.